Shockwave Reducer

Treating the pain of refractory angina is now possible, even if your patient’s discomfort is uncontrollable by traditional medical therapies. Shockwave Reducer is an innovative technology designed to provide much-needed relief to patients suffering from the symptoms of refractory angina by creating a permanent, controlled narrowing of the coronary sinus.*

Coronary Sinus Reduction for Refractory Angina   Shockwave Reducer Overview and MOA
Digital rendering of reducer device
Digital rendering of reducer device

Ingeniously Designed for Angina Treatment

Millions of patients with coronary artery disease (CAD) suffer from refractory angina despite receiving optimal medical therapy, and are not candidates for revascularization. Enter Shockwave Reducer. 

Shockwave Reducer is a small, balloon-expandable, hourglass-shaped device that establishes a narrowing in the coronary sinus. The resulting increase in back pressure reduces angina symptoms by a hypothesized redistribution of blood into the ischemic myocardium.1  

Before Shockwave Reducer, there were limited options for treating refractory angina. Now, an effective, innovative solution is on hand for patients and physicians alike to improve perfusion to ischemic myocardium.

Digitally rendered image of Shockwave Reducer device showing the balloon catheter and the narrow central neck.
Shockwave Reducer at EuroPCR 2025: Reducer Mechanism of Action

Shockwave Reducer MOA

At EuroPCR 2025, Prof. Spratt (St George’s Hospital, London) reviewed the hypothesized mechanism of action (MOA) of the Shockwave Reducer device, first exploring how flow is maintained in a healthy heart versus a diseased heart, before diving into how Shockwave Reducer works to redistribute flow.

EuroPCR 2025 | Road to Relief: Effective Treatment of Refractory Angina Patients with Shockwave Reducer

At EuroPCR 2025, anchorperson James Spratt, spokesperson Felix Woitek and discussants Ranil de Silva, Mariusz Tomaniak and Tommaso Gori took the stage to present “Road to Relief: Effective Treatment of Refractory Angina Patients with Shockwave Reducer.”

In this symposium, the physicians discuss:

Watch the Symposium

The physicians featured are paid consultants for Shockwave Medical. 

See the Impact for Patients

See More

Individual patient stories may vary.

Resources

See All Products

1: Verheye S., et al. N Engl J Med 2015;372:519-27. 

*Shockwave Reducer is commercially available in select European countries and has been implanted in over 3,500 patients. It is currently under clinical investigation in the U.S.

CAUTION: In the United States, Shockwave Reducer is an investigational device, limited by United States law to investigational use. Shockwave Reducer is subject of investigational testing and is being studied in the COSIRA-II trial in Canada. Shockwave Reducer is commercially available in certain countries outside the U.S. and Canada. Please contact your local representative for specific country availability. Prior to use, please reference the Instructions for Use for more information on warnings, precautions and adverse events: ifu.sw-reducer.com